ClinicalTrials.gg
CompletedNCT04391374Updated May 3, 2023

Hemostatic Endothelial Dysfunction in Patients With Peripheral Artery Disease

An observational study in Peripheral Artery Disease, Restenosis of Peripheral Vascular Stent and Restenosis, Vascular Graft, sponsored by Ryazan State Medical University. Completed. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Ryazan State Medical University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
167
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide II (NO) metabolites, plasmin activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), coagulation factor VIII (FVIII), soluble endothelial protein C receptors (sEPCR)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.

Read the detailed description

The study will involve patients with atherosclerotic peripheral artery disease (Rutherford category 3-5). The subjects are to be divided into three groups:

Group A: patients who undergo bypass surgery with a synthetic graft on aorto-iliac or femoro-popliteal segment; Group B: patients who undergo endovascular balloon angioplasty and stenting on aorto-iliac or femoro-popliteal segment; Group C: patients who undergo standard of care conservative treatment.

Decisions on revascularization or conservative treatment alone is to be made by a team of vascular specialists in accordance with the severity of the disease, previous treatment, anatomy, possible need for repeat procedures in the future, and patient's preferences.

02

Conditions studied

  • Peripheral Artery Disease
  • Restenosis of Peripheral Vascular Stent
  • Restenosis, Vascular Graft
  • Endothelial Dysfunction

Keywords

  • hemostasis, endothelial dysfunction, restenosis, thrombosis
03

In context

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

This study's enrollment of 167 is below the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A prospective study is aimed at enrolling 200 patients with atherosclerotic peripheral arterial disease, Rutherford category 3-5. The patients with PAD are scheduled to undergo either open or endovascular reconstructive procedures on aorto-iliac and femoro-popliteal segment or conservative treatment alone. The subjects of similar age, sex, and ethnicity are to be divided into three groups, respectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females older than 40 years of age;
  2. Presence of peripheral arterial disease of atherosclerotic origin.

Exclusion criteria

Exclusion Criteria:

  1. Males or females younger than 40 years of age;
  2. Chronic lower limb ischemia of other ethiology (Buerger's disease, aortoarteritis etc.);
  3. Active cancer or remission period less than 5 years;
  4. Decompensated diabetes mellitus;
  5. Pregnancy or breast-feeding for females.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
167 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Conservative treatment

    Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.

  • Peripheral artery bypass grafting

    Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position

    Procedure: an arterial reconstructive procedure

  • Peripheral artery balloon angioplasty and stenting

    Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position

    Procedure: an arterial reconstructive procedure

Interventions

  • Procedurean arterial reconstructive procedure
06

What researchers measure

Primary outcomes

  1. thrombosis

    incidence of thrombotic complications in the target arterial segment

    Time frame: 1 year

  2. restenosis

    incidence of restenosis in the target arterial segment

    Time frame: 1 year

  3. progression of atherosclerosis

    detection of newly formed or progressing peripheral atherosclerotic lesions

    Time frame: 1 year

Secondary outcomes

  1. limb salvage rate

    limb salvage rate in the target extremity

    Time frame: 1 year

  2. acute myocardial infarction

    incidence of acute myocardial infarction

    Time frame: 1 year

  3. mortality rate

    overall mortality rate

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kalinin RE, Suchkov IA, Mzhavanadze ND, Zhurina ON, Klimentova EA, Povarov VO. Coagulation Factor Activity and Hemostatic Markers of Endothelial Dysfunction in Patients with Peripheral Arterial Disease. Vasc Specialist Int. 2021 Aug 5;37:26. doi: 10.5758/vsi.210010. PubMed 34349046 ↗
  • Kalinin RE, Suchkov IA, Mzhavanadze ND, Demikhov VG, Zhurina ON, Klimentova EA. [Hemostatic changes in patients with peripheral artery disease before and after bypass surgery]. Khirurgiia (Mosk). 2018;(8):46-49. doi: 10.17116/hirurgia2018846. Russian. PubMed 30113592 ↗

Individual participant data

Plan to share: Undecided — Basic demographic data, including sex, age, and ethnicity are to be shared if allowed by the privacy policy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2023, 73 months.

Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's 73 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 18, 2020
StartActual
Jan 2017
Primary completionActual
Feb 23, 2023
CompletionActual
Mar 23, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04391374
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
May 18, 2020
Start date
Jan 2017
Primary completion
Feb 23, 2023
Completion
Mar 23, 2023
Last update
May 3, 2023

Study contacts

Nina Mzhavanadze, MD, PhD
principal investigator · RyazSMU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion